Chemokine MCP1 is Associated with Cognitive Flexibility in Schizophrenia: A Preliminary Analysis

Overview

Journal J Psychiatr Res

Specialty Psychiatry

Date 2021 Apr 14

PMID 33852994

Citations 9

Authors

Federica Klaus

Kyle Mitchell

Sharon C Liou

Lisa T Eyler

Tanya T Nguyen

Affiliations

Soon will be listed here.

Abstract

Background: Peripheral levels of pro-inflammatory biomarkers have been shown to be altered in schizophrenia (SZ) and associated with cognitive impairments, but their relevance to specific cognitive domains remains unclear.

Methods: Plasma levels of cytokines, chemokines, and vascular biomarkers were quantified and compared between SZ and healthy comparison (HC) groups. Cognition was assessed using the Delis-Kaplan Executive Function System Trail Making (TM) and Color Word Interference (CWI) tests. Linear regression analyses examined differential relationships of inflammatory biomarkers with executive function between groups.

Results: Plasma levels of TNFα, ICAM1, and MCP1 were higher in individuals with SZ compared to HCs. Higher level of MCP1 was associated with increased CWI Inhibition Switching Errors in SZ but not HCs.

Conclusion: Like other studies, we found evidence for increased peripheral inflammation in SZ. We also showed that SZ with particularly high MCP1 levels had poor cognitive flexibility. Interventions to reduce chemokine elevations might prove beneficial for cognitive performance.

Citing Articles

Variations in inflammatory regulators in male patients with chronic schizophrenia associated with psychopathology and cognitive deficits.

Guo T, Chen L, Luan L, Yang M, Zhang X, Yang H BMC Psychiatry. 2024; 24(1):811.

PMID: 39548412 PMC: 11566147. DOI: 10.1186/s12888-024-06288-9.

Photodynamic Therapy as a Novel Therapeutic Modality Applying Quinizarin-Loaded Nanocapsules and 3D Bioprinting Skin Permeation for Inflammation Treatment.

do Amaral S, Amantino C, Atanasov A, Sousa S, Moakes R, Oliani S Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338332 PMC: 11434822. DOI: 10.3390/ph17091169.

Li X, Hu S, Liu P Front Psychiatry. 2023; 14:1241422.

PMID: 37692299 PMC: 10486913. DOI: 10.3389/fpsyt.2023.1241422.

Cytokine alterations in CSF and serum samples of patients with a first episode of schizophrenia: results and methodological considerations.

Singh D, Guest P, Dobrowolny H, Fischbach T, Meyer-Lotz G, Breitling-Ziegler C Eur Arch Psychiatry Clin Neurosci. 2023; 273(6):1387-1393.

PMID: 36773080 PMC: 10449694. DOI: 10.1007/s00406-023-01569-y.

Single-nucleus RNA sequencing of midbrain blood-brain barrier cells in schizophrenia reveals subtle transcriptional changes with overall preservation of cellular proportions and phenotypes.

Puvogel S, Alsema A, Kracht L, Webster M, Weickert C, Sommer I Mol Psychiatry. 2022; 27(11):4731-4740.

PMID: 36192459 PMC: 9734060. DOI: 10.1038/s41380-022-01796-0.

References

Kirkpatrick B, Messias E, Harvey P, Fernandez-Egea E, Bowie C . Is schizophrenia a syndrome of accelerated aging?. Schizophr Bull. 2007; 34(6):1024-32. PMC: 2632500. DOI: 10.1093/schbul/sbm140. View

Lee E, Hong S, Martin A, Eyler L, Jeste D . Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. Am J Geriatr Psychiatry. 2016; 25(1):50-61. PMC: 5164855. DOI: 10.1016/j.jagp.2016.09.009. View

Goldsmith D, Rapaport M, Miller B . A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016; 21(12):1696-1709. PMC: 6056174. DOI: 10.1038/mp.2016.3. View

Hong S, Lee E, Martin A, Soontornniyomkij B, Soontornniyomkij V, Achim C . Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Schizophr Res. 2016; 181:63-69. PMC: 5357211. DOI: 10.1016/j.schres.2016.09.019. View

Ribeiro-Santos A, Teixeira A, Salgado J . Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol. 2014; 12(3):273-80. PMC: 4023457. DOI: 10.2174/1570159X1203140511160832. View

Homack S, Lee D, Riccio C . Test review: Delis-Kaplan executive function system. J Clin Exp Neuropsychol. 2005; 27(5):599-609. DOI: 10.1080/13803390490918444. View

Spitzer R, Williams J, GIBBON M, First M . The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry. 1992; 49(8):624-9. DOI: 10.1001/archpsyc.1992.01820080032005. View

Stuart M, Baune B . Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev. 2014; 42:93-115. DOI: 10.1016/j.neubiorev.2014.02.001. View

Green M, Horan W, Lee J . Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry. 2019; 18(2):146-161. PMC: 6502429. DOI: 10.1002/wps.20624. View

10.

Beumer W, Drexhage R, de Wit H, Versnel M, Drexhage H, Cohen D . Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012; 37(12):1901-11. DOI: 10.1016/j.psyneuen.2012.04.001. View

11.

Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski J, Samochowiec J, Frydecka D . Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res. 2017; 192:16-29. DOI: 10.1016/j.schres.2017.04.015. View

12.

Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B . Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging. 2005; 27(12):1763-8. DOI: 10.1016/j.neurobiolaging.2005.10.007. View

13.

Pillinger T, Osimo E, Brugger S, Mondelli V, McCutcheon R, Howes O . A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. Schizophr Bull. 2018; 45(5):1120-1133. PMC: 6737479. DOI: 10.1093/schbul/sby160. View

14.

Insel T . Rethinking schizophrenia. Nature. 2010; 468(7321):187-93. DOI: 10.1038/nature09552. View

15.

Horn S, Long M, Nelson B, Allen N, Fisher P, Byrne M . Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis. Brain Behav Immun. 2018; 73:85-114. PMC: 6800199. DOI: 10.1016/j.bbi.2018.06.016. View

16.

Rajji T, Ismail Z, Mulsant B . Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2009; 195(4):286-93. DOI: 10.1192/bjp.bp.108.060723. View

17.

Wilson C, Cohen H, Pieper C . Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. J Am Geriatr Soc. 2003; 51(10):1374-81. DOI: 10.1046/j.1532-5415.2003.51454.x. View

18.

Vohringer P, Barroilhet S, Amerio A, Reale M, Alvear K, Vergne D . Cognitive impairment in bipolar disorder and schizophrenia: a systematic review. Front Psychiatry. 2013; 4:87. PMC: 3737461. DOI: 10.3389/fpsyt.2013.00087. View

19.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H . CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018; 91(9):e867-e877. PMC: 6133624. DOI: 10.1212/WNL.0000000000006082. View

20.

Savla G, Twamley E, Thompson W, Delis D, Jeste D, Palmer B . Evaluation of specific executive functioning skills and the processes underlying executive control in schizophrenia. J Int Neuropsychol Soc. 2010; 17(1):14-23. PMC: 3616491. DOI: 10.1017/S1355617710001177. View